The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer

Esophageal cancer (EC) is one of the most common cancers with poor survival in the world. Nowadays, a generous number of clinical trials are underway on the use of immunotherapy in EC patients, especially the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. However, only a few p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hui, Wang, Kunlun, Wang, Tao, Li, Mengxi, Li, Bingxu, Li, Shenglei, Yuan, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066251/
https://www.ncbi.nlm.nih.gov/pubmed/32195194
http://dx.doi.org/10.3389/fonc.2020.00300
_version_ 1783505209916391424
author Yang, Hui
Wang, Kunlun
Wang, Tao
Li, Mengxi
Li, Bingxu
Li, Shenglei
Yuan, Ling
author_facet Yang, Hui
Wang, Kunlun
Wang, Tao
Li, Mengxi
Li, Bingxu
Li, Shenglei
Yuan, Ling
author_sort Yang, Hui
collection PubMed
description Esophageal cancer (EC) is one of the most common cancers with poor survival in the world. Nowadays, a generous number of clinical trials are underway on the use of immunotherapy in EC patients, especially the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. However, only a few patients could benefit from single-agent therapy. Others need combination therapies to enhance the response rate and survival. In this review, we focus on PD-1/PD-L1 inhibitors and its combination options in EC patients. We also summarized the potential predictive biomarkers for PD-1/PD-L1 inhibitors treatment.
format Online
Article
Text
id pubmed-7066251
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70662512020-03-19 The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer Yang, Hui Wang, Kunlun Wang, Tao Li, Mengxi Li, Bingxu Li, Shenglei Yuan, Ling Front Oncol Oncology Esophageal cancer (EC) is one of the most common cancers with poor survival in the world. Nowadays, a generous number of clinical trials are underway on the use of immunotherapy in EC patients, especially the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. However, only a few patients could benefit from single-agent therapy. Others need combination therapies to enhance the response rate and survival. In this review, we focus on PD-1/PD-L1 inhibitors and its combination options in EC patients. We also summarized the potential predictive biomarkers for PD-1/PD-L1 inhibitors treatment. Frontiers Media S.A. 2020-03-05 /pmc/articles/PMC7066251/ /pubmed/32195194 http://dx.doi.org/10.3389/fonc.2020.00300 Text en Copyright © 2020 Yang, Wang, Wang, Li, Li, Li and Yuan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Hui
Wang, Kunlun
Wang, Tao
Li, Mengxi
Li, Bingxu
Li, Shenglei
Yuan, Ling
The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
title The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
title_full The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
title_fullStr The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
title_full_unstemmed The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
title_short The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
title_sort combination options and predictive biomarkers of pd-1/pd-l1 inhibitors in esophageal cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066251/
https://www.ncbi.nlm.nih.gov/pubmed/32195194
http://dx.doi.org/10.3389/fonc.2020.00300
work_keys_str_mv AT yanghui thecombinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT wangkunlun thecombinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT wangtao thecombinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT limengxi thecombinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT libingxu thecombinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT lishenglei thecombinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT yuanling thecombinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT yanghui combinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT wangkunlun combinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT wangtao combinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT limengxi combinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT libingxu combinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT lishenglei combinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer
AT yuanling combinationoptionsandpredictivebiomarkersofpd1pdl1inhibitorsinesophagealcancer

Ejemplares similares